SUPN

Over the past six months, Supernus Pharmaceuticals experienced several significant stock events. On April 1, 2026, the company secured intellectual property and development rights for SPN-820. On May 5, 2026, it reported Q1 CY2026 financial results, with revenue exceeding estimates but GAAP loss per share missing consensus. A major event occurred on August 1, 2026, when Supernus entered a definitive all-stock merger agreement with Indivior Pharmaceuticals, aiming to create a diversified CNS biopharmaceutical leader. This was announced on August 3, 2026, alongside Q2 CY2026 financial results, which saw revenue surpass expectations and full-year operating income guidance exceed estimates, leading to a 24.9% stock increase to $55.75. On August 31, 2026, Chloe Kim partnered with Qelbree for ADHD awareness, and on September 2, 2026, Supernus announced participation in investor conferences. However, on October 1, 2026, shares declined due to turbulence in its Viloxazine patent case and investor frustration over the pending Indivior merger, specifically regarding a special cash dividend for Indivior holders not extended to Supernus shareholders, and new law firm probes into the deal's fairness. On October 6, 2026, a $1 billion Indivior dividend was noted in the merger valuations. Over the past year, the stock declined 11.3%, with the largest daily drop of 17.4% on November 5, 2025.